New patent paves way for breast cancer prevention

November 20, 2015 by Michele Mcdonald
Virginia “Ginny” Espina and Lance Liotta at the Center for Applied Proteomics and Molecular Medicine. Credit: Creative Services photo.

George Mason University researchers have patented a new breast cancer treatment that uses a common malaria drug to stop cancer in its beginning stages.

Chloroquine, a drug commonly given to prevent or treat malaria, targets "ductal carcinoma in situ," or DCIS, the most common type of pre-invasive breast cancer. DCIS is the main precursor to invasive, metastatic, and lethal, breast cancer.

DCIS shows up as white spots in a breast MRI. Those white spots are calcifications that may mark where DCIS are growing in the milk ducts, said Virginia "Ginny" Espina, a researcher at George Mason's Center for Applied Proteomics and Molecular Medicine who spearheaded the work and holds the patent with center co-director Lance Liotta. Not every instance of DCIS becomes cancer, but the majority of breast cancer goes through the DCIS stage, she said.

Chloroquine works by killing off the pre-invasive cells that are accumulating in the milk ducts. Any drug, including , which acts on this same target is covered under the patent. The malaria drug has few side effects, Espina said.

The patent is a significant step in combating breast cancer because it will pave the way for drug companies to develop chloroquine-like treatments to kill the cancer before it starts, Liotta said.

Women could take chloroquine as a cancer preventative as a matter of course, Espina said.

"When your cells realize they don't have enough nutrients, they eat pieces of themselves," Espina said. "It's a way to make energy when you don't have enough food."

And that's the spot the DCIS cells are in as they pile up in the milk duct. They're not getting enough oxygen and food and are squashed together.

"It's like being in a crowded elevator," Espina said. "You're next to people but not necessarily next to people you know or like. It's the same way for these tumor cells or pre-invasive cells. They're next to a cell, but they're crowded, hungry and not anchored anywhere, and cells like to be anchored and have a home.

"For all these reasons, they're under stress. When a cell is under stress, it's a life-and-death struggle. They're not just going to die. They're going to do what they can to survive."

Chloroquine works like Pepto-Bismol; it alters the cell's digestive process and stops them from making energy, Espina said. The pre-invasive cells die but the healthy cells are not affected.

GMU's Virginia "Ginny" Espina holds a patent that could change how breast cancer is treated and prevented. Credit: George Mason University, Creative Services

Currently, patients with pre-invasive breast cancer are told to "watch and wait" or to have a lumpectomy or a preventative mastectomy, Liotta said.

"Some doctors tell patients to leave it alone and watch it over time because it may not become invasive, or recommend surgery followed by hormone-based and/or radiation treatment," Liotta said. "But we know that if you do nothing, then there's a high likelihood that the cells will become invasive. Chloroquine treatment provides an additional treatment option, even for those women who choose watchful waiting and surgical therapy."

In 2008, Espina developed the idea to use chloroquine against cells after reading research and using the in another project. "We just tried it, which is how most of our advances have been made."

The research is part of an ongoing clinical trial, the PINC Trial (Preventing Invasive breast Neoplasia with Chloroquine).

Explore further: George Mason University researchers target breast cancer in three trials

Related Stories

George Mason University researchers target breast cancer in three trials

November 1, 2012
A malarial drug is showing promise in stopping breast cancer before it starts, Mason researchers are discovering during a clinical trial.

High-grade DCIS detection rates increase in older women

October 27, 2015
The mammography detection rate of an early-stage but potentially invasive type of breast cancer rises with age, according to a large new study from Germany published online in the journal Radiology.

Study gives insight into breast cancer recurrence

November 5, 2014
Work by University of Manchester scientists has explored what allows some cases of Ductal Carcinoma in Situ (DCIS), a non-invasive form of breast cancer, to resist treatment and come back, as well as identifying a potential ...

Potential for prediction of progression for early form of breast cancer

April 15, 2015
Scientists in Manchester have identified a way to potentially predict which patients with an early form of breast cancer will experience disease progression.

Benefit of surgery for ductal carcinoma in-situ investigated

June 3, 2015
In a study published in JAMA Surgery on June 3, researchers from Brigham and Women's Hospital (BWH) report that breast surgery performed at or shortly after a diagnosis of low-grade ductal carcinoma in-situ (DCIS) did not ...

Recommended for you

Shooting the achilles heel of nervous system cancers

July 20, 2017
Virtually all cancer treatments used today also damage normal cells, causing the toxic side effects associated with cancer treatment. A cooperative research team led by researchers at Dartmouth's Norris Cotton Cancer Center ...

Molecular changes with age in normal breast tissue are linked to cancer-related changes

July 20, 2017
Several known factors are associated with a higher risk of breast cancer including increasing age, being overweight after menopause, alcohol intake, and family history. However, the underlying biologic mechanisms through ...

Immune-cell numbers predict response to combination immunotherapy in melanoma

July 20, 2017
Whether a melanoma patient will better respond to a single immunotherapy drug or two in combination depends on the abundance of certain white blood cells within their tumors, according to a new study conducted by UC San Francisco ...

Discovery could lead to better results for patients undergoing radiation

July 19, 2017
More than half of cancer patients undergo radiotherapy, in which high doses of radiation are aimed at diseased tissue to kill cancer cells. But due to a phenomenon known as radiation-induced bystander effect (RIBE), in which ...

Definitive genomic study reveals alterations driving most medulloblastoma brain tumors

July 19, 2017
The most comprehensive analysis yet of medulloblastoma has identified genomic changes responsible for more than 75 percent of the brain tumors, including two new suspected cancer genes that were found exclusively in the least ...

Novel CRISPR-Cas9 screening enables discovery of new targets to aid cancer immunotherapy

July 19, 2017
A novel screening method developed by a team at Dana-Farber/Boston Children's Cancer and Blood Disorders Center—using CRISPR-Cas9 genome editing technology to test the function of thousands of tumor genes in mice—has ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.